文献速递神经胸部MRCT

多模态影像组学分析确定与非小细胞肺癌脑转移表皮生长因子受体突变相关的高一致性预后表型

Multimodal radiomic analysis to determine high-Consistency prognostic phenotypes associated with epidermal growth factor receptor mutations in non-small cell lung cancer brain metastases.
PubMed 文献 · Eur J Radiol · 2025-09-15

本研究纳入2008至2020年间接受放射外科治疗的318例非小细胞肺癌脑转移患者共759个病灶,利用脑MR和CT图像构建EGFR相关影像组学标签(EGFR-RS),其一致性优于全影像组学特征标签(WF-RS);EGFR-RS是局部复发的独立预测因子,联合EGFR突变状态和病灶大小的临床-影像组学模型对高危复发灶的识别优于临床模型。

要点

  • EGFR-RS由11个MR和6个CT的EGFR相关预后影像组学特征构成,一致性优于WF-RS。
  • EGFR-RS在测试队列的C指数为0.746(95%CI 0.616, 0.876),高于WF-RS的0.655(95%CI 0.527, 0.784)。
  • 临床-影像组学模型(EGFR-RS+EGFR突变状态+BM大小)识别局部复发高危病灶优于临床模型。

核心结论

  • 多模态EGFR-RS一致性优于WF-RS,能有效预测非小细胞肺癌脑转移的局部复发。

研究设计与样本

  • 回顾性分析2008至2020年接受放射外科治疗的非小细胞肺癌脑转移患者的脑MR和CT图像,共318例患者759个脑转移灶;采用LASSO筛选特征并构建标签,以C指数评估区分能力,用单因素和多因素竞争风险回归确定预测因子并建立临床-影像组学模型。

诊断标准与关键数值

  • EGFR-RS包含11个MR和6个CT的EGFR相关预后影像组学特征;测试队列C指数0.746(95%CI 0.616, 0.876),WF-RS为0.655(95%CI 0.527, 0.784)。

临床应用与阅片要点

  • 多因素分析显示EGFR-RS在发现集(P < 0.001,HR = 2.75)和测试集(P = 0.01,HR = 2.13)均为局部复发的唯一显著预测因子;临床-影像组学模型在发现集(P < 0.001,HR = 4.54)和测试集(P = 0.002,HR = 5.1)识别局部复发高危病灶优于临床模型。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

INTRODUCTION: Limited linkage between epidermal growth factor receptor (EGFR) mutations and recurrence-predictive radiomic signatures restricts the application of radiomics-guided therapy for brain metastases (BMs) from non-small-cell lung cancer (NSCLC). This study aimed to establish an EGFR-associated radiomic signature (EGFR-RS), compare its consistency with that of conventional whole radiomic features-based radiomic signature (WF-RS), and evaluate its efficacy in predicting local recurrence for BMs treated with radiosurgery.

METHODS: Brain magnetic resonance (MR) and computed tomography (CT) images of NSCLC patients with BMs undergoing radiosurgery between 2008 and 2020 were examined. The least absolute shrinkage and selection operator was utilized to select features and develop signatures. Discriminative abilities were assessed using the area under the curve, while univariable and multivariable competing risk regression determined predictors and established a clinical-radiomic model.

RESULTS: In total, 318 patients with 759 BMs were enrolled. The EGFR-RS, incorporating 11 MR and six CT EGFR-associated prognostic radiomic features, displayed better consistency, and superior predictive performance than the WF-RS, with C-indices of 0.746 (95 %CI 0.616, 0.876) in the test cohort, compared with 0.655 (95 %CI 0.527, 0.784) for the WF-RS. Multivariable analysis indicated EGFR-RS as the sole significant predictor of local recurrence in both the discovery and test sets (P < 0.001, hazard ratio [HR] = 2.75; and P = 0.01, HR = 2.13, respectively). The clinical-radiomic model (EGFR-RS + EGFR mutation status + BM size) outperformed the clinical model in identifying high-risk lesions with local recurrence (discovery: P < 0.001; HR = 4.54; test: P = 0.002; HR = 5.1).

CONCLUSION: The multimodal EGFR-RS, demonstrating better consistency than the WF-RS, effectively predicted the local recurrence of NSCLC BMs.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Hsu CY, Tsai HH, Chen TL, et al. Multimodal radiomic analysis to determine high-Consistency prognostic phenotypes associated with epidermal growth factor receptor mutations in non-small cell lung cancer brain metastases. Eur J Radiol. 2025. PMID: 41016079. doi:10.1016/j.ejrad.2025.112420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。